A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (STOP-HS2)

• ClinicalTrials.gov Identifier: NCT05620836
• Recruitment Status: Recruiting
• First Posted: November 17, 2022
• Last Update Posted: May 10, 2024
• Sponsor: Incyte Corporation
• Information provided by (Responsible Party): Incyte Corporation

Tracking Information

• First Submitted Date: November 10, 2022
• First Posted Date: November 17, 2022
• Last Update Posted Date: May 10, 2024
• Actual Study Start Date: February 22, 2023
• Estimated Primary Completion Date: March 11, 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: November 10, 2022)

Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR) [ Time Frame: Week 12 ]

HiSCR is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: November 10, 2022)

• Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) [ Time Frame: Week 12 ]
  HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.
• Proportion of participants with flare [ Time Frame: 12 Weeks ]
  Participants who experience at least 1 flare over 12 weeks; flare is defined as at least a 25% increase in the total abscess and inflammatory nodule count with a minimum increase of 2 relative to baseline.
• Proportion of participants with a ≥ 3-point decrease in Skin Pain Numeric Rating Scale (NRS) score among participants with baseline Skin Pain NRS score ≥ 3 [ Time Frame: Week 12 ]
  Participants with a Skin Pain score of at least 3 at baseline and who experience at least a 3-point decrease in Skin Pain score at Week 12, relative to baseline. Skin Pain is an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain).
• Proportion of participants who achieve Skin Pain NRS30 at Week 12 among participants with baseline Skin Pain NRS score ≥ 3. [ Time Frame: Week 12 ]
  Participants with a Skin Pain score of at least 3 at baseline and who achieve at Week 12 Skin Pain NRS30, defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Skin Pain NRS.
• Proportion of participants with a ≥ 4-point increase from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) score [ Time Frame: Week 12 ]
  Participants with a baseline FACIT-F score ≤ 48 and who experience at least a 4-point increase in FACIT-F score at Week 12, relative to baseline. The FACIT-F scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days, with scores ranging from 0 (worst fatigue) to 52 (no fatigue).
• Mean change from baseline in Dermatology Life Quality Index (DLQI) score [ Time Frame: 54 weeks ]
  The DLQI is a skin disease specific questionnaire aimed at the evaluation of how symptoms and treatment affect participants' health-related quality of life (QoL). The DLQI total score ranges from 0 to 30, with higher scores indicating lower skin health related QoL.
• Mean change from baseline in abscess count [ Time Frame: 54 weeks ]
  Defined as mean change of abscess(es) count relative to baseline.
• Percentage change from baseline in abscess count [ Time Frame: 54 weeks ]
  Percent Change from baseline in number of abscess(es)
• Mean change from baseline in inflammatory nodule count [ Time Frame: 54 weeks ]
  Defined as mean change of inflammatory nodule count relative to baseline.
• Percentage change from baseline in inflammatory nodule count [ Time Frame: 54 weeks ]
  Defined as percent change from baseline in number of inflammatory nodule(s)
• Mean change from baseline in draining tunnel count [ Time Frame: 54 weeks ]
  Defined as mean change of draining tunnel count relative to baseline.
• Percentage change from baseline in draining tunnel count [ Time Frame: 54 weeks ]
  Defined as Percent change from baseline in number of draining tunnel(s)
• Extension Period: Proportion of participants who achieve HiSCR [ Time Frame: Week 24 ]
  HiSCR is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.
• Extension Period: Proportion of participants who achieve HiSCR75 [ Time Frame: Week 24 ]
  HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.
• Extension Period: Proportion of participants with flare [ Time Frame: From Week 12 through Week 24 ]
  Participants who experience at least 1 flare over the period under assessment; flare is defined as at least a 25% increase in the total abscess and inflammatory nodule count with a minimum increase of 2 relative to baseline.
• Extension Period: Proportion of participants who achieved Skin Pain NRS30 among participants with baseline Skin Pain NRS score ≥ 3. [ Time Frame: Week 24 ]
  Skin Pain NRS30 defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Skin Pain NRS.
• Extension Period: Proportion of participants who achieve HiSCR [ Time Frame: Week 54 ]
  HiSCR is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.
• Extension Period: Proportion of participants who achieve HiSCR75 [ Time Frame: Week 54 ]
  HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.
• Extension Period: Proportion of participants with flare [ Time Frame: From Week 12 through Week 54 ]
  Participants who experience at least 1 flare over the period under assessment; flare is defined as at least a 25% increase in the total abscess and inflammatory nodule count with a minimum increase of 2 relative to baseline
• Extension Period: Proportion of participants who achieved Skin Pain NRS30 among participants with baseline Skin Pain NRS score ≥ 3. [ Time Frame: Week 54 ]
  Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS30, defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Skin Pain NRS.
• Extension Period: Proportion of participants who achieve maintenance of HiSCR or greater response at each visit [ Time Frame: From Week 12 through Week 54 ]
  Maintenance of response defined as participants who achieve HiSCR at Week 12 and maintain it or achieve greater response at each visit during the EXT period.
• Extension Period: Proportion of participants who achieve maintenance of HiSCR75 or greater response at each visit [ Time Frame: From Week 12 through Week 54 ]
  Maintenance of response defined as participants who achieve HiSCR75 at Week 12 and maintain it or achieve greater response at each visit during the EXT period.

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
• Official Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
• Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Participants will be randomized 1:1:1 to Povorcitinib Dose A, Povorcitinib Dose B, or Placebo once a day (QD); participants who complete the placebo-controlled (PC) 12-week period may continue to a 42-week extension (EXT) period with Povorcitinib (Dose A or Dose B) QD.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

• Condition: Hidradenitis Suppurativa (HS)

Intervention

• Drug: Povorcitinib
  Oral, Tablet
  Other Name: INCB054707
• Drug: Placebo
  Oral, Tablet

Study Arms

• Experimental: Povorcitinib Dose A
  Participants will receive Povorcitinib Dose A for 54 weeks.
  Intervention: Drug: Povorcitinib
• Experimental: Povorcitinib Dose B
  Participants will receive Povorcitinib Dose B for 54 weeks.
  Intervention: Drug: Povorcitinib
• Placebo Comparator: Placebo
  Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.
  Intervention: Drug: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: November 10, 2022): 600
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: January 30, 2026
• Estimated Primary Completion Date: March 11, 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Male and female participants ≥ 18 years of age.
• Diagnosis of moderate to severe HS ≥ 3 months prior to Screening visit.
• HS lesions present in ≥ 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the Screening and Baseline visits.
• Total abscess and inflammatory nodule (AN) count ≥ 5 at both the Screening and Baseline visits.
• History of inadequate response to an appropriate course of at least 1 conventional systemic therapy for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for HS)
• Agree to not use certain topical antiseptics on the areas affected by HS lesions during the placebo-controlled period.
• Willingness to avoid pregnancy or fathering children.
• Other inclusion criteria apply.

Exclusion Criteria:

• Draining tunnel count of > 20 at Screening or Baseline visits.
• Women who are pregnant (or who are considering pregnancy) or breastfeeding.
• Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
• Evidence of infection with TB, HBV, HCV or HIV.
• History of failure to JAK inhibitor treatment of any inflammatory disease.
• Laboratory values outside of the protocol-defined ranges.
• Other exclusion criteria apply.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Incyte Corporation Call Center (US); 1.855.463.3463; medinfo@incyte.com

Contact: Incyte Corporation Call Center (ex-US); +800 00027423; eumedinfo@incyte.com

• Listed Location Countries: Australia, Bulgaria, Canada, Denmark, France, Germany, Italy, Poland, Spain, United Kingdom, United States

Administrative Information

• NCT Number: NCT05620836
• Other Study ID Numbers: INCB 54707-302
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Yes

Plan Description

Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

• Supporting Materials: Study Protocol
• Supporting Materials: Statistical Analysis Plan (SAP)
• Time Frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
• Access Criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
• URL: https://www.incyte.com/our-company/compliance-and-transparency

• Current Responsible Party: Incyte Corporation
• Original Responsible Party: Same as current
• Current Study Sponsor: Incyte Corporation
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Incyte Corporation
• Verification Date: May 2024